<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03827122</url>
  </required_header>
  <id_info>
    <org_study_id>RC/IRB/2018/1247</org_study_id>
    <nct_id>NCT03827122</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A Injectable Solution in the Management of Bruxism: A Clinical Trial Study</brief_title>
  <official_title>Botulinum Toxin A Injectable Solution in the Management of Bruxism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riyadh Colleges of Dentistry and Pharmacy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Riyadh Colleges of Dentistry and Pharmacy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Trial Study to investigate the potential performance of BTXA on masseter muscle on
      patient with nocturnal bruxism and to check the pain scale and share this clinical
      experience.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Experimental group we will use BTX-A administration group. All patients (Male/Female) with
      bruxism associated with chronic pain in masseter muscles bilaterally participated in this
      study. The patients age 18-60 years. According to the diagnostic grading system of bruxism
      all subjects will have an assessment including a bruxism questionnaire (i.e., oral history
      taking with specific focus on bruxism habits) plus a clinical examination to evaluate bruxism
      signs and symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2018</start_date>
  <completion_date type="Anticipated">November 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single group with bruxism they will be injected in masster muscles bilaterally</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain reduction after botox injection subjective</measure>
    <time_frame>Change in clenching after 2,8,16,48 weeks</time_frame>
    <description>Visual pain scale with a score from 0 to 10</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Nocturnal Bruxism</condition>
  <arm_group>
    <arm_group_label>Group one</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botx will be injection in masster muscles 20unit Botx (onabotulinumtoxinA) and visual pain scale will be taken before and after in four intervals 2,8,16,48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>onabotulinumtoxinA</intervention_name>
    <description>Experimental group we will use BTX-A administration group. All patients (Male/Female) with bruxism associated with chronic pain in masseter muscles bilaterally Patients will have treatment with 20 units of BOTOX, (Allergan Inc.) per side will be injected at three points into masseter muscle bilaterally.</description>
    <arm_group_label>Group one</arm_group_label>
    <other_name>Botox Allergan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Moderate to severe pain in relation to the masseter muscles and TMJ area related to
             bruxism during clinical examination.

          2. Aged 20-60 patients.

          3. Tooth-grinding sounds corroborated by family members or caregivers.

          4. Cases where bruxism resulted in occlusal surface attrition of posterior teeth

        Exclusion Criteria:

          1. pain in the orofacial region,

          2. insomnia,

          3. known botulinum toxin allergy,

          4. pregnancy,

          5. neuromuscular disease,

          6. bleeding disorders,

          7. antibiotic therapy,

          8. pulmonary disease that produced coughing during sleep,

          9. infectious skin lesion at the site of the injection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baraa abdulrahman, BDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Riyadh Colleges of Dentistry and Pharmacy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Baraa abdulrahman, BDS</last_name>
    <phone>+966582766220</phone>
    <email>Baraa.abdulrahman@riyadh.edu.sa</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riyadh Elm University</name>
      <address>
        <city>Riyadh</city>
        <zip>11681</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baraa abdulrahman</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>January 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 1, 2019</study_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Riyadh Colleges of Dentistry and Pharmacy</investigator_affiliation>
    <investigator_full_name>Baraa Abdulrahman</investigator_full_name>
    <investigator_title>Master Resident in Oral Diagnostics</investigator_title>
  </responsible_party>
  <keyword>Bruxism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bruxism</mesh_term>
    <mesh_term>Sleep Bruxism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

